Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05664126
Other study ID # VSTHCT
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 1, 2023
Est. completion date December 31, 2027

Study information

Verified date March 2024
Source St. Jude Children's Research Hospital
Contact Naik Swati, MD
Phone 866-278-5833
Email referralino@stjude.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators want to learn if CMV- and ADV-specific T-cells (cells that fight infections) isolated (selected) from a donor using an automated medical device can be a safe treatment for treating patients with CMV, and ADV after transplant.This study will test the effects and safety of giving VSTs produced here at St. Jude in treating the participant's infection. Primary objective To determine the efficacy of VSTs to achieve a ≥1 log10 reduction in CMV and/or ADV viral load in the peripheral blood 4 weeks after VST infusion. When the initial viral load is <1 log10 above the threshold of detection, the objective is to achieve a reduction to below the threshold of detection. Secondary objectives - Determine the safety of VSTs when used to treat CMV and/or ADV viremia post-HCT. - Determine the proportion of patients who achieve a negative viral load at 3 months post-infusion. - Assess the persistence of response for 6 months post-infusion.


Description:

The study will have 2 cohorts. Cohort A will include haploidentical donor who is identical to the stem cell donor. Cohort B will include haploidentical donor who is different from the stem cell donor. Seropositive donors will be screened for the presence of CMV- and ADV-specific T-cells using a functional flow cytometry assay. The donor will be considered suitable if the percentage of CD3+/IFN-γ+ cells is greater than 0.01% of CD3+ T-cells. Donor leukocytes will be collected using the Spectra Optia system. CMV- and ADV-specific T-cells will be isolated from donor leukocytes by 'IFN-γ-capture' technology using the Prodigy device over a 24-36 hour period and infused.


Recruitment information / eligibility

Status Recruiting
Enrollment 64
Est. completion date December 31, 2027
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group N/A to 18 Years
Eligibility Inclusion Criteria: - Patients who have undergone haploidentical HCT or a matched-sibling/matched-unrelated donor HCT, and have CMV and/or ADV detected by PCR in the peripheral blood refractory to antiviral therapy per institutional BMTCT SOP 20.05. - Definition of "refractory" viremia is persistent positive CMV or ADV viremia after 14 days of treatment per institutional SOP, or an increasing copy number (=1 log) after 7 days of treatment. - Patients have no suspected or confirmed GVHD. - Availability of haploidentical donor for isolation of virus-specific T-cells. - Have not received a Donor Lymphocyte Infusion in the past 4 weeks. - Female patients of childbearing age must have a negative pregnancy test. - Subject, parent, or guardian are capable of giving signed informed consent. - Patients must have a shortening fraction >26% or left ventricular ejection fraction >40%. - Patients must have a bilirubin less than or equal to 2.5mg/dL and alanine aminotransferase (ALT) less than or equal to 5 times the upper limit of normal. - Patients must have an estimated glomerular filtration rate (GFR) greater than 60mL/min/1.73m2. - Patients must be free of severe infection which upon determination of the principal investigator precludes therapy with VST. - Patients must have FVC >50% predicted or if unable to perform pulmonary function testing must maintain pulse oximetry saturation > 92% on room air. - Patients must have engrafted with an ANC >500 cells/mm3 for 3 consecutive days. Inclusion criteria for donors - Age =18 years. - At least single haplotype matched (=3/6) family member. - Donor will be identical to the stem cell donor (Cohort A) or different from the stem cell donor (Cohort B). - HIV negative. - For females of childbearing age: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment AND not lactating with intent to breastfeed. - Regarding donation eligibility, is identified as either having completed the process of donor eligibility determination as outlined in 21CFR 1271 and agency guidance or does not meet 21CFR 1271 eligibility requirements but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21CFR. - Identified recipient with CMV and/or ADV reactivation post-HCT. Exclusion Criteria: - Active GVHD. - Pregnancy. - Inability to provide consent. - Need for vasopressor or ventilatory support Patients receiving steroids >0.5 mg/kg prednisone equivalent at the time of VST infusion - Donor Lymphocyte Infusion within 4 weeks prior to VST infusion. - Receipt of Thymoglobulin or Alemtuzumab within 30 days of VST infusion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
VST infusion
single intravenous (IV) infusion.
Device:
CliniMACS
Cells infusions are prepared using the ClinMACS

Locations

Country Name City State
United States St . Jude Children's Research Hospital Memphis Tennessee

Sponsors (1)

Lead Sponsor Collaborator
St. Jude Children's Research Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Degree of reduction of CMV and/or ADV viral load The primary objective of this clinical study is to evaluate the efficacy of adoptively transferred CMV- and ADV-specific haploidentical T-cells in patients who have undergone allogeneic HCT. This primary endpoint is defined as =1 log10 reduction in CMV and/or ADV viral load 4 weeks after VST infusion. When the initial viral load is <1 log10 above the threshold of detection the endpoint will be a reduction to below the threshold of detection. The success rate will be evaluated using descriptive statistics (sample proportion and standard error). Patients with both CMV and ADC detected will count as success if reduction occurs in one or both of CMV and ADV. 4 weeks after VST infusion
Secondary Incidence of infusion-related grade 3-5 adverse events 24 hours after infusion The incidence of infusion-related grade 3-5 adverse events will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors) 24 hours after infusion
Secondary Incidence of AEs related to grade 3-4 cytokine release syndrome (CRS), or grade 1-2 CRS persist beyond 72 hours despite therapy The incidence of AEs related to grade 3-4 cytokine release syndrome (CRS), or grade 1-2 CRS persist beyond 72 hours despite therapy will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors) 4 weeks after VST infusion
Secondary Incidence of Grade 3-4 Neurotoxicity of any duration The incidence of Grade 3-4 Neurotoxicity of any duration will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors) 4 weeks after VST infusion
Secondary Incidence of Grade 3-4 GVHD The incidence of Grade 3-4 GVHD will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors) 4 weeks after VST infusion
Secondary Incidence of grade 3-5 non hematologic toxicities attributable to VST The incidence of grade 3-5 non hematologic toxicities attributable to VST will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors) 4 weeks after VST infusion
Secondary Incidence of secondary graft failure attributable to VST The incidence of secondary graft failure attributable to VST will be estimated using descriptive statistics (sample proportions and cumulative incidence curves with standard errors) 4 weeks after VST infusion
Secondary Proportion of patients who achieve a negative viral load result at 3 months The proportion of patients who achieve a negative viral load result at 3 months will be assessed using descriptive statistics (sample proportions with standard errors) 3 months after VST infusion
Secondary Persistence of response at 6 months post-infusion The persistence of response at 6 months post-infusion will be assessed using descriptive statistics (sample proportions with standard errors) 6 months after VST infusion
See also
  Status Clinical Trial Phase
Completed NCT01195571 - Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age Phase 1
Recruiting NCT01248598 - The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis N/A
Active, not recruiting NCT05575492 - A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age Phase 1/Phase 2
Recruiting NCT03665675 - Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT Early Phase 1
Completed NCT00456664 - CMV Disease and IRIS in HIV-1 Infected Persons N/A
Completed NCT04840199 - A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. Phase 2
Active, not recruiting NCT05397223 - A Study of Modified mRNA Vaccines in Healthy Adults Phase 1
Completed NCT02452229 - Review of Human Herpes Viruses in Burns N/A
Completed NCT01160081 - Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis N/A
Completed NCT00467532 - Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients N/A
Terminated NCT03127787 - Clinical Performance Evaluation of DxN CMV Assay
Completed NCT00366717 - Cytomegalovirus Reactivation in Cancer Patients Receiving Chemotherapy N/A
Completed NCT00815802 - Detection of Human Cytomegalovirus in the Saliva N/A
Completed NCT01646645 - Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Suspended NCT00668798 - Cytomegalovirus (CMV) Transmission by Frozen Breast Milk in Preterms N/A
Completed NCT00214240 - The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease N/A
Completed NCT00330018 - Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT) Phase 3
Completed NCT01895049 - Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria Phase 4
Completed NCT02083042 - Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients N/A
Completed NCT01162330 - The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment N/A